356 related articles for article (PubMed ID: 7405678)
1. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
Wiles DH; Gelder MG
Adv Biochem Psychopharmacol; 1980; 24():599-602. PubMed ID: 7405678
[No Abstract] [Full Text] [Related]
2. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
Wiles DH; Gelder MG
Br J Clin Pharmacol; 1979 Dec; 8(6):565-70. PubMed ID: 533577
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine.
Marder SR; Van Putten T; Aravagiri M; Hubbard JW; Hawes EM; McKay G; Midha KK
Psychopharmacol Bull; 1989; 25(3):479-82. PubMed ID: 2626520
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
[TBL] [Abstract][Full Text] [Related]
5. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
Tsutsul'kovskaia MIa; Minsker EI; Panteleeva GP; Mazurskii MB; Pekunova LG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(5):753-8. PubMed ID: 4718619
[No Abstract] [Full Text] [Related]
6. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
Brown WA; Silver MA
J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
[TBL] [Abstract][Full Text] [Related]
7. Plasma fluphenazine levels measured by high-performance liquid chromatography in patients treated with depot injections.
Jouen F; Verité P; André D; Colonna L; Boucly P
Arzneimittelforschung; 1993 May; 43(5):509-11. PubMed ID: 8328993
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunoassay for 7-hydroxy metabolite of fluphenazine and its application to plasma level monitoring in schizophrenic patients treated long term with oral and depot fluphenazine.
Aravagiri M; Marder SR; Van Putten T; Hawes EM; McKay G; Midha KK
Ther Drug Monit; 1994 Feb; 16(1):21-9. PubMed ID: 8160250
[TBL] [Abstract][Full Text] [Related]
9. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
Tune LE; Creese I; Coyle JT; Pearlson G; Snyder SH
Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
[TBL] [Abstract][Full Text] [Related]
10. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
Cookson JC; Kennedy NM; Gribbon D
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
[TBL] [Abstract][Full Text] [Related]
11. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Jayaram G; Coyle J; Tune L
J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
[TBL] [Abstract][Full Text] [Related]
12. [Prolonged treatment of schizophrenic psychoses with depot-fluphenazine ("lyogen decanoate")].
Bohacek N; Mihovilović M
Neuropsihijatrija; 1968; 16(3):69-73. PubMed ID: 5195835
[No Abstract] [Full Text] [Related]
13. Plasma fluphenazine levels in patients receiving two doses of fluphenazine decanoate.
Marder SR; Hubbard JW; Van Putten T; Hawes EM; McKay G; Mintz J; May PR; Midha KK
Psychopharmacol Bull; 1986; 22(1):264-6. PubMed ID: 3726072
[No Abstract] [Full Text] [Related]
14. Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics. Some preliminary findings.
Turbott J; Villiger J; Hunter L
Br J Psychiatry; 1985 Apr; 146():439-42. PubMed ID: 4016448
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
[No Abstract] [Full Text] [Related]
16. Depot fluphenazine and plasma prolactin.
Gift T; Plum K; Price M
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):407-12. PubMed ID: 4070643
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity.
Soni SD; Wiles D; Schiff AA; Bamrah JS
Br J Psychiatry; 1988 Sep; 153():382-4. PubMed ID: 3250675
[TBL] [Abstract][Full Text] [Related]
18. Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals.
Norman TR; Marriott PF; Kimber NM; Burrows GD
Int Clin Psychopharmacol; 1987 Oct; 2(4):299-305. PubMed ID: 3693869
[TBL] [Abstract][Full Text] [Related]
19. Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen [proceedings].
Schooler NR; Levine J; Severe JB
Psychopharmacol Bull; 1979 Apr; 15(2):44-7. PubMed ID: 373006
[No Abstract] [Full Text] [Related]
20. Fluphenazine plasma levels and clinical response.
Marder SR; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J; Midha KK
Psychopharmacol Bull; 1990; 26(2):256-9. PubMed ID: 2236467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
